{"id":7037988,"date":"2026-08-15T16:43:35","date_gmt":"2026-08-15T16:43:35","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/new-research-from-the-cwmh-data-on-the-reproductive-safety-of-vortioxetine\/"},"modified":"2026-08-15T16:43:35","modified_gmt":"2026-08-15T16:43:35","slug":"new-research-from-the-cwmh-data-on-the-reproductive-safety-of-vortioxetine","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7037988","title":{"rendered":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p><span style=\"font-weight: 400;\">Vortioxetine (Trintellix) is an antidepressant used for the treatment of major depressive disorder in adults. While we have a considerable amount of information supporting the reproductive safety of older antidepressants, including most selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine, and bupropion, we have far less information on newer antidepressants.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Vortioxetine was approved in the United States in 2013 for the treatment of depression. Because it is a relatively newer antidepressant, the number of reported pregnancies with vortioxetine exposure has been small. Analyzing data from the MGH National Pregnancy Registry for Psychiatric Medications, <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42370714\/\"><span style=\"font-weight: 400;\">Freeman and colleagues now report additional prospective data<\/span><\/a><span style=\"font-weight: 400;\"> on the risk of major malformations following first-trimester exposure to vortioxetine.<\/span><\/p>\n<h2><b>The National Pregnancy Registry<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The <\/span><a href=\"https:\/\/womensmentalhealth.org\/research\/pregnancyregistry\/antidepressants\/\"><span style=\"font-weight: 400;\">National Pregnancy Registry for Psychiatric Medications<\/span><\/a><span style=\"font-weight: 400;\"> is a prospective pharmacovigilance program. Pregnant women with a history of psychiatric illness are enrolled during pregnancy and followed through the postpartum period. Information is collected before the pregnancy outcome is known, an important feature that reduces the risk of recall and reporting bias.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For this analysis, the investigators:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Identified women enrolled in the Registry who reported taking vortioxetine during the first trimester<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Collected information about major malformations through a maternal postpartum interview and review of medical records<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Used a dysmorphologist who was blinded to medication exposure to make the final determination regarding major malformations<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">As of March 26, 2026, 56 women with first-trimester exposure to vortioxetine had evaluable outcome data.\u00a0<\/span><\/p>\n<h2><b>No Major Malformations Observed After First-Trimester Exposure<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Among the 56 women who used vortioxetine during the first trimester, no major malformations were observed.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Vortioxetine-exposed pregnancies:<\/b><span style=\"font-weight: 400;\"> 0 of 56 with a major malformation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Outcome assessment:<\/b><span style=\"font-weight: 400;\"> Maternal postpartum interview, medical-record review, and adjudication by a dysmorphologist blinded to exposure status<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">These preliminary findings are reassuring. The new study did not identify a signal suggesting that vortioxetine is a major teratogen.\u00a0<\/span><\/p>\n<p><b>Reassuring Findings, But More Research is Needed<\/b><\/p>\n<p><span style=\"font-weight: 400;\">The new Registry findings add important information to a previously sparse literature. The study provides systematically collected data because women were enrolled prospectively and outcomes were assessed through postpartum interviews and medical-record review.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">At the same time, the sample remains small. Observing no malformations among 56 exposed pregnancies does not establish that vortioxetine is safe during pregnancy. These data cannot rule out a modest increase in risk, nor can they detect rare malformations. Much larger numbers of exposed pregnancies and an appropriate comparison group will be needed to generate a more precise estimate of risk.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It is also important to note that the analysis focused on major malformations after first-trimester exposure. It does not provide information on other outcomes that may be relevant when an antidepressant is used during pregnancy, including miscarriage, pregnancy complications, preterm birth, neonatal adaptation symptoms, or longer-term neurodevelopmental outcomes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Taken together, these findings offer some reassurance regarding the risk of major malformations following first-trimester exposure to vortioxetine. However, treatment decisions must be individualized. When initiating an antidepressant in a person who is pregnant or planning pregnancy, it is reasonable to consider a medication with a better-characterized reproductive safety profile. For a patient who has responded well to vortioxetine, however, the potential benefits of switching medications must be weighed against the risk of relapse or loss of treatment response.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">No two situations are identical. Decisions regarding treatment should take into account the severity and recurrence of the mother\u2019s illness, her response to previous medications, the availability of effective alternatives, and the risks associated with untreated depression during pregnancy.\u00a0<\/span><\/p>\n<p><b>The Registry Continues to Recruit<\/b><\/p>\n<p><span style=\"font-weight: 400;\">The<\/span><a href=\"https:\/\/womensmentalhealth.org\/research\/pregnancyregistry\/antidepressants\/\"> <span style=\"font-weight: 400;\">National Pregnancy Registry for Antidepressants<\/span><\/a><span style=\"font-weight: 400;\"> continues to enroll pregnant people age 45 and younger with a history of psychiatric illness. People who have taken an antidepressant during pregnancy, as well as those who have not taken an antidepressant, are eligible to participate.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Participation helps clinicians and patients make better-informed decisions about the use of antidepressant medications during pregnancy. To learn more, visit our website or call <\/span><b>1-866-961-2388<\/b><span style=\"font-weight: 400;\">.\u00a0<\/span><\/p>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Vortioxetine (Trintellix) is an antidepressant used for the treatment of major depressive disorder in adults. While we have a considerable amount of information supporting the reproductive safety of older antidepressants, including most selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine, and bupropion, we have far less information on newer antidepressants. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[200552,200553,200554,200555,200556,102090,200549,200557,177006,12394,200558,200559,200560,200561,200550,200551,200562,200563],"tags":[200564,11603,28747,10113,417,200565],"dealstore":[],"offerexpiration":[],"class_list":["post-7037988","post","type-post","status-publish","format-standard","hentry","category-antidepressant-safety","category-antidepressants-in-pregnancy","category-first-trimester-exposure","category-major-congenital-malformations","category-major-depressive-disorder","category-maternal-mental-health","category-medications-and-pregnancy","category-newer-antidepressants","category-perinatal-psychiatry","category-pregnancy","category-pregnancy-registry","category-prenatal-medication-exposure","category-psychiatric-medications","category-reproductive-safety","category-research-at-cwmh","category-risk-of-malformations","category-trintellix","category-vortioxetine","tag-cwmh","tag-data","tag-reproductive","tag-research","tag-safety","tag-vortioxetine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=7037988\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Vortioxetine (Trintellix) is an antidepressant used for the treatment of major depressive disorder in adults. While we have a considerable amount of information supporting the reproductive safety of older antidepressants, including most selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine, and bupropion, we have far less information on newer antidepressants. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=7037988\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-15T16:43:35+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=7037988#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=7037988\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine\",\"datePublished\":\"2026-08-15T16:43:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7037988\"},\"wordCount\":656,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"keywords\":[\"CWMH\",\"Data\",\"Reproductive\",\"Research\",\"Safety\",\"Vortioxetine\"],\"articleSection\":[\"antidepressant safety\",\"antidepressants in pregnancy\",\"first trimester exposure\",\"major congenital malformations\",\"major depressive disorder\",\"maternal mental health\",\"Medications and Pregnancy\",\"newer antidepressants\",\"Perinatal Psychiatry\",\"Pregnancy\",\"pregnancy registry\",\"prenatal medication exposure\",\"psychiatric medications\",\"reproductive safety\",\"Research at CWMH\",\"Risk of Malformations\",\"Trintellix\",\"vortioxetine\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=7037988#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=7037988\",\"url\":\"https:\/\/fivemor.com\/?p=7037988\",\"name\":\"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"datePublished\":\"2026-08-15T16:43:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=7037988#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=7037988\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=7037988#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=7037988","og_locale":"en_US","og_type":"article","og_title":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network","og_description":"Vortioxetine (Trintellix) is an antidepressant used for the treatment of major depressive disorder in adults. While we have a considerable amount of information supporting the reproductive safety of older antidepressants, including most selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine, and bupropion, we have far less information on newer antidepressants. [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=7037988","og_site_name":"Som2ny Network","article_published_time":"2026-08-15T16:43:35+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=7037988#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=7037988"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine","datePublished":"2026-08-15T16:43:35+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=7037988"},"wordCount":656,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"keywords":["CWMH","Data","Reproductive","Research","Safety","Vortioxetine"],"articleSection":["antidepressant safety","antidepressants in pregnancy","first trimester exposure","major congenital malformations","major depressive disorder","maternal mental health","Medications and Pregnancy","newer antidepressants","Perinatal Psychiatry","Pregnancy","pregnancy registry","prenatal medication exposure","psychiatric medications","reproductive safety","Research at CWMH","Risk of Malformations","Trintellix","vortioxetine"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=7037988#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=7037988","url":"https:\/\/fivemor.com\/?p=7037988","name":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"datePublished":"2026-08-15T16:43:35+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=7037988#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=7037988"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=7037988#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7037988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7037988"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7037988\/revisions"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7037988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7037988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7037988"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=7037988"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=7037988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}